Annual report pursuant to Section 13 and 15(d)

Intangibles (Schedule of JMC Recognized Expense Related to its Product Licenses) (Details)

v3.21.1
Intangibles (Schedule of JMC Recognized Expense Related to its Product Licenses) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Finite-Lived Intangible Assets [Line Items]    
Beginning balance $ 7,377 $ 1,417
Research and development 2,834 6,090
Additions:   7,134
Amortization expense (1,420) (1,174)
Ending balance 14,629 7,377
Ximino [Member]    
Finite-Lived Intangible Assets [Line Items]    
Beginning balance 7,100  
Ending balance 5,690 $ 7,100
Anti-itch Product [Member]    
Finite-Lived Intangible Assets [Line Items]    
Additions: 3,945  
Amortization expense 0  
Oral Acne Product (Isotretinoin) [Member]    
Finite-Lived Intangible Assets [Line Items]    
Additions: 4,727  
Amortization expense $ 0